Faeth Therapeutics (FTH) grants CEO 398,018 performance-based options
Rhea-AI Filing Summary
Faeth Therapeutics, Inc. granted President and CEO Anand Kiran Parikh a performance-based stock option covering 398,018 shares of common stock at a $28.3700 exercise price, expiring in 2036. The option vests only if a sustained $70.00 stock-price hurdle and time-and-service conditions are met. In a qualifying Change in Control where per-share consideration is at least $70.00, it vests in full; if the $70.00 hurdle is not achieved by the fourth anniversary of grant, or not deemed achieved in connection with a Change in Control, the option is forfeited.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Parikh Anand Kiran
Role
President and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Performance-Based Stock Option (right to buy) F1, F2 | 398,018 | $0.00 | $0.00 |
Holdings After Transaction:
Performance-Based Stock Option (right to buy) — 398,018 shares (Direct)
Footnotes (2)
- F1. Represents a performance-based stock option that becomes exercisable, if at all, on the later of (i) the first date on which the average closing price of the Issuer's common stock on the Nasdaq Stock Market over any 30 consecutive calendar-day period equals or exceeds $70.00 (the "Stock Price Hurdle") and (ii) the first anniversary of the date of grant, in each case subject to the Reporting Person's continued service with the Issuer as of each such date. If the Stock Price Hurdle is not achieved by the fourth anniversary of the date of grant (the "Performance Period"), the option will be forfeited in its entirety.
- F2. In the event of a Change in Control (as defined in the Issuer's 2026 Equity Incentive Plan) of the Issuer prior to the end of the Performance Period, the Stock Price Hurdle will be deemed achieved if the per-share consideration payable in the transaction equals or exceeds $70.00 (subject to equitable adjustment). If so deemed achieved, the option will vest in full immediately prior to the consummation of the Change in Control, subject to the Reporting Person's continued service with the Issuer through such time. If the Stock Price Hurdle is not achieved or deemed achieved in connection with the Change in Control, the option will be forfeited in its entirety.
Key Figures
Option grant size: 398,018 shares
Exercise price: $28.3700 per share
Underlying common shares: 398,018 shares
+2 more
5 metrics
Option grant size
398,018 shares
Performance-based stock option awarded to President and CEO
Exercise price
$28.3700 per share
Conversion or exercise price of the performance-based stock option
Underlying common shares
398,018 shares
Shares of common stock underlying the performance-based option
Stock Price Hurdle
$70.00 per share
Average closing price over any 30-day period required for vesting
Option expiration date
2036-07-20
Expiration date of the performance-based stock option grant
Key Terms
Performance-Based Stock Option, Stock Price Hurdle, Change in Control, Equity Incentive Plan
4 terms
Performance-Based Stock Option financial
"Represents a performance-based stock option that becomes exercisable, if at all, on the later of"
Stock Price Hurdle financial
"the average closing price of the Issuer's common stock over 30 days equals or exceeds $70.00, the Stock Price Hurdle"
Change in Control financial
"In the event of a Change in Control of the Issuer prior to the end of the Performance Period"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
Equity Incentive Plan financial
"Change in Control (as defined in the Issuer's 2026 Equity Incentive Plan) of the Issuer"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Faeth Therapeutics (FTH) report in this Form 4?
Faeth Therapeutics reported a grant of performance-based stock options to its President and CEO, Anand Kiran Parikh. The award covers 398,018 shares of common stock at a $28.3700 exercise price and is structured with stringent performance and service-based vesting conditions.
How many performance-based stock options were granted to the Faeth Therapeutics (FTH) CEO?
The CEO received a performance-based stock option covering 398,018 shares of Faeth Therapeutics common stock. These options are not immediately exercisable and only vest if both stock-price and time-and-service conditions are satisfied, otherwise the entire award can be forfeited.
What is the exercise price and expiration date of the Faeth Therapeutics (FTH) CEO option grant?
The option has a $28.3700 exercise price per share and expires on July 20, 2036. This long-dated option provides potential future upside but only if the vesting requirements tied to stock performance and continued service are ultimately met.
What stock-price hurdle must be met for the Faeth Therapeutics (FTH) option to vest?
Vesting requires the average closing price of Faeth’s common stock to reach at least $70.00 over any 30 consecutive days. This Stock Price Hurdle must be met in addition to a minimum one-year service requirement and overall performance period conditions.
How does a Change in Control affect the Faeth Therapeutics (FTH) CEO’s performance option?
If a Change in Control occurs and per-share consideration is at least $70.00, the performance hurdle is deemed achieved and the option vests in full immediately before closing. If the hurdle is not achieved or deemed achieved, the option is forfeited in its entirety.
What happens if Faeth Therapeutics (FTH) does not hit the $70 stock-price target within the performance period?
If the $70.00 Stock Price Hurdle is not achieved by the fourth anniversary of the grant date, the performance-based option is forfeited. This means the CEO would receive no shares from this award if the hurdle and timing conditions are not satisfied.